Insider Transactions in Q2 2023 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 26
2023
|
Eric Venker President & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
72,906
+8.87%
|
$218,718
$3.85 P/Share
|
|
Apr 26
2023
|
Rakhi Kumar Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
87,830
-30.5%
|
$702,640
$8.68 P/Share
|
|
Apr 26
2023
|
Rakhi Kumar Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
87,830
+14.05%
|
$263,490
$3.91 P/Share
|
|
Apr 20
2023
|
Richard Pulik CFO |
BUY
Grant, award, or other acquisition
|
Direct |
66,710
+18.78%
|
-
|
|
Apr 20
2023
|
Rakhi Kumar Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,569
-0.78%
|
$12,552
$8.8 P/Share
|
|
Apr 20
2023
|
Rakhi Kumar Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,710
+24.85%
|
-
|
|
Apr 20
2023
|
Matthew Gline CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,375
-1.8%
|
$155,000
$8.8 P/Share
|
|
Apr 20
2023
|
Eric Venker President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,457
-2.09%
|
$115,656
$8.8 P/Share
|
|
Apr 03
2023
|
Ilan Oren |
BUY
Grant, award, or other acquisition
|
Direct |
1,942
+3.03%
|
-
|
|
Apr 03
2023
|
James C Momtazee |
BUY
Grant, award, or other acquisition
|
Direct |
1,351
+2.16%
|
-
|